Clinical trials: B ALL
Stevens-Johnson Syndrome, Kidney Failure, Chronic
HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction
Allopurinol-induced severe cutaneous adverse reaction (SCAR) is a rare but fatal condition. Previous reports have reported that HLA-B*5801 is an important genetic risk factor significantly associated with the development of…
- Trial name
- NCT03046914
- Testing
- HLA-B*5801 test
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Seoul National University Hospital
Non-Hodgkin's Lymphoma, B-cell Lymphoma
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug, bevacizumab and whether this treatment is feasible in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00788606
- Testing
- bevacizumab, Rituximab
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Chronic Hepatitis B
Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients
The most important method to slow down and stop the liver disease progression in patients with chronic hepatitis B is antiviral therapy, by which to achieve maintaining viral response during treatment or obtain sustained viral…
- Trial name
- NCT02387684
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Decompensated Hepatitis B Cirrhosis
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1.
- Trial name
- FZHYRORDFDHBLC (NCT07017426)
- Testing
- Fuzheng Huayu tablets
- Volunteers
- 432 people
- Sponsor
- Zhiyun Yang
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Vaccine Reaction
Evaluation of Immunoprotection Provided by Hepatitis B Vaccine After Birth in Healthy Children
Worldwide, hepatitis B virus (HBV) infection is a major cause of acute hepatitis,and chronic infection with HBV often leads to chronic hepatitis, liver cirrhosis,and hepatocellular carcinoma.
- Trial name
- NCT04439435
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Cancer, Chronic Lymphocytic Leukemia (CLL)
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
This observational study will evaluate the safety and effectiveness of Venetoclax used in routine clinical practice for participants diagnosed with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT04178317
- Where
- 13 sites in South Korea
- Volunteers
- 14 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in…
- Trial name
- NCT00507689
- Testing
- FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Explicit Recall of Intra-operative Events
Study Evaluating Ways of Preventing Patients From Being Awake During High-Risk Surgery and Anesthesia
The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during…
- Trial name
- NCT00281489
- Testing
- BIS Monitor guided algorithm, Volatile anesthetic guided algorithm
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine
Cirrhosis Due to Hepatitis B
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV…
- Trial name
- NCT02238860
- Testing
- Entacavir, Tenofovir
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Asian Institute Of Medical Sciences
Hepatitis B
Hepatitis B Seroepidemiology Among Young Adults
Taiwan has launched a successful nationwide neonatal hepatitis B immunization since July 1, 1984. It successfully decreased the incidence of hepatitis B virus infection, the hepatitis B carrier rate as well as liver diseases…
- Trial name
- NCT01973582
- Where
- Taiwan
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
- Trial name
- NCT07231952
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Infertility
Oocyte Vitrification Aided With Cytochalasin B
Using the cytoskeleton Stabilizer the Cytochalasin B would improve the outcome of oocyte vitrification.
- Trial name
- NCT03678558
- Testing
- Cytochalasin B supplemented vitrification medium
- Where
- Egypt
- Volunteers
- 612 people
- Sponsor
- Ibn Sina Hospital
Diffuse Large B-cell Lymphoma
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity.
- Trial name
- DLBCL (NCT01186978)
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Hemophilia
Bleeding Symptoms of Carriers of Hemophilia A and B
To collect and analyze data on female carriers of severe and moderate hemophilia A and B.
- Trial name
- NCT01029808
- Where
- Sweden
- Volunteers
- 126 people
- Sponsor
- Sahlgrenska University Hospital
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Lymphoma, Large B-Cell, Diffuse
Durvalumab in DLBCL After Autologous Transplant
The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.
- Trial name
- IDA-D (NCT03241017)
- Testing
- Durvalumab
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Solid Tumor, Adult
Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors
This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled anti-ED-B mAbs SPECT imaging in patients with ED-B positive solid tumors.
- Trial name
- NCT05623891
- Testing
- 177Lu-B5-IgG4
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Affiliated Hospital of Jiangnan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.